Patients with age-related macular degeneration may soon see their monthly injection become an annual refill, with potentially better results
A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months in between treatments. This represents a vast improvement over the typical regimen of nearly monthly eye injections. The researchers involved in the Phase II clinical study say the implant is not just about convenience; a more consistent treatment will also help people keep more of their vision. They are presenting their research today at AAO 2018, the 122nd Annual Meeting of the American Academy of Ophthalmology.
A lead researcher from Wills Eye Hospital in Philadelphia is presenting results from the LADDER study evaluating the efficacy and safety of an investigational, long-acting port delivery system for Lucentis (ranibizumab), a drug that improves vision for millions across the globe suffering from age-related macular degeneration.
The multicenter, randomized trial included 220 patients. The study determined the time until a patient needed a refill of the implant. It also evaluated the effectiveness of three different concentrations of Lucentis compared with monthly injections of the drug.
Before Lucentis was introduced 12 years ago, people with wet AMD were almost certain to develop severe vision loss or blindness. Lucentis was the first treatment to slow the disease, allowing more than 90 percent of patients to keep their vision, according to clinical trials. However, in the real world, the percentage is closer to 50 percent. One of the main reasons why is that patients are undertreated. This is because most people with AMD must go to the ophthalmologist’s office every six to eight weeks to keep their vision. This can be a difficult schedule to maintain for many elderly patients struggling with other maladies and reliant on others to get them to their ophthalmologist visits.
Researchers have been searching for a better alternative to monthly injections almost from the moment Lucentis was introduced. One of the latest ideas is to surgically implant a refillable drug reservoir device, slightly longer than a grain of rice, into the eye. Filled with a concentrated version of Lucentis, the device, called the port delivery system, delivers drug to the back of the eye over a longer time frame.
Lead site investigator, Carl D. Regillo, M.D., chief of retina service and professor of Ophthalmology at Wills Eye Hospital, said that patients treated with the highest drug concentration were able to go a median of 15 months before needing a refill. Port delivery treatment was also as effective as monthly injections.
“Fewer injections and office visits is exciting,” said Dr. Regillo, who administers more than 100 injections a week. “But more importantly, we think it will translate into better visual outcomes because in the real world, patients get less treatment than they need. It’s not done consciously. Over time, things happen: illness, hospitalization, a snowstorm, etc. and appointments are missed or delayed. If you’re a week or two late for a visit from time to time, you may have a decline in vision, and you can’t always recover from that. It’s a relentlessly progressive disease.”
The study did find some side effects from surgery, but the overall safety profile was good. The device is not visible on the outside of the eye. It’s implanted under the eyelid, appearing, at most, as a tiny dot. After the initial surgery, it can be refilled during an office visit.
Dr. Regillo anticipates that the new delivery system could be available to patients in about three years.
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Gene therapy first to halt most common cause of blindness on February 19, 2019 at 3:42 am
LONDON: Oxford researchers claim to have carried out the world's first gene therapy operation to halt age-related macular degeneration (AMD), the leading cause of untreatable blindness in the develope... […]
- Experimental gene therapy treatment used to try to stop most common cause of blindness in aging people on February 18, 2019 at 11:38 pm
(Gray News) – For the first time, a woman with the most common cause of blindness – age-related macular degeneration – has been treated with an experimental gene therapy in the hopes it will halt the ... […]
- What is wet macular degeneration on February 18, 2019 at 12:53 pm
Millions of people deal with age-related macular degeneration as they get older, but many don’t understand the difference between types of the condition or what they can do to lessen the effects. Dr S... […]
- Is a cure for blindness in sight? Scientists launch first attempt to halt most common cause of age-related blindness with gene therapy on February 18, 2019 at 6:36 am
Now the surgeons have launched their first attempt at halting age-related macular degeneration - known as AMD - which is the most common cause of blindness and affects 600,000 people in the UK. The te... […]
- Macular Degeneration on February 17, 2019 at 1:50 pm
Age-related macular degeneration (AMD) is a chronic disease of the macula, the central area of the retina, and is the leading cause of irreversible vision loss in the developed world. AMD is classifie... […]
- Protect Your Aging Eyes From Macular Degeneration on February 15, 2019 at 2:00 pm
FRIDAY, Feb. 15, 2019 (HealthDay News) -- Age-related macular degeneration (AMD) is an incurable eye disease that affects millions of older Americans, but there are a number of things you can do to re... […]
- What you need to know about wet macular degeneration on February 14, 2019 at 6:35 am
Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or what they can do to lessen the effects. […]
- Top 7 Healthy Habits to Help Prevent Macular Degeneration on February 12, 2019 at 8:17 pm
Doctors aren't sure what causes age-related macular degeneration, a disease that affects millions of people in the United States. Also called AMD, it is known for causing blurred central vision due to ... […]
- What you need to know about Age-related Macular Degeneration. on February 12, 2019 at 4:01 am
(BPT) - The ability to see the people, places and things in front of you is one of life’s most precious gifts. Imagine a life without the ability to see these things clearly — what steps would you the... […]
via Bing News